Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0614620080510050291
Korean Journal of Gastroenterology
2008 Volume.51 No. 5 p.291 ~ p.297
The Frequency and the Course of the Adverse Effects of Azathioprine/6-Mercaptopurine Treatment in Patients with Inflammatory Bowel Disease
Kim Jae-Hak

Cheon Jae-Hee
Kim Won-Ho
Abstract
Background/Aims: This study was to evaluate the frequency and the course of the adverse effects of AZA/6-MP in Korean patients with inflammatory bowel disease (IBD).

Methods: Medical records of the patients with IBD treated with AZA/6-MP at Severance hospital from June 1996 to September 2006 were retrospectively analyzed.

Results: A total of 133 patients were studied. Male to female ratio was 1.3:1. The mean age was 31.7¡¾10.9 year. Adverse effects included leukopenia occurred in 75 cases (56.4%), nausea/vomiting in 32 cases (24.1%), arthralgia in 6 cases (4.5%), hepatitis in 6 cases (4.5%), skin rash in 4 cases (3.0%), herpes zoster in 3 cases (2.3%), and headache in 1 case (0.8%). Most of leucopenia (58.7%) developed within 3 months after maximal tolerated dose of AZA/6-MP and nausea/vomiting frequently occurred within 3 months after start of AZA/6-MP treatment. Thirty-eight patients (28.6%) required the discontinuation of medication due to adverse effects.

Conclusion: Leukopenia was the most common adverse effect of AZA/6-MP treatment. Leukopenia and nausea/ vomiting developed frequently in the early period of treatment of AZA/6-MP in patients with IBD. AZA/6-MP should be used cautiously to scrutinize bone marrow suppression.
KEYWORD
Azathioprine, 6-Mercaptopurine, Adverse effects, Leukopenia, Inflammatory bowel disease
FullTexts / Linksout information
 
Listed journal information
MEDLINE ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø